Literature DB >> 23162135

Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting.

Christopher Sundling1, Paola Martinez, Martina Soldemo, Mats Spångberg, Karin Lövgren Bengtsson, Linda Stertman, Mattias N E Forsell, Gunilla B Karlsson Hedestam.   

Abstract

The envelope glycoproteins (Env) represent a critical component of a successful antibody-mediated human immunodeficiency virus type 1 (HIV-1) vaccine. However, immunization with soluble Env was reported to induce short-lived antibody responses, suggesting that Env has unusual immunogenic properties. Here, we directly compared the magnitude and durability of B-cell responses induced by HIV-1 Env and an unrelated soluble viral protein, influenza virus hemagglutinin (HA), in simultaneously inoculated macaques. We demonstrate robust peak responses followed by rapid contraction of circulating antibody and memory B cells for both antigens, suggesting that short-lived responses are not unique to HIV-1 Env but may be a common feature of soluble protein vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23162135     DOI: 10.1093/infdis/jis696

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

Review 1.  What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.

Authors:  Dennis R Burton
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

2.  Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

Authors:  Robert J O'Connell; Jean-Louis Excler; Victoria R Polonis; Silvia Ratto-Kim; Josephine Cox; Linda L Jagodzinski; Michelle Liu; Lindsay Wieczorek; John G McNeil; Raphaelle El-Habib; Nelson L Michael; Bruce L Gilliam; Robert Paris; Thomas C VanCott; Georgia D Tomaras; Deborah L Birx; Merlin L Robb; Jerome H Kim
Journal:  J Infect Dis       Date:  2016-02-11       Impact factor: 5.226

Review 3.  Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Authors:  George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

Review 4.  HIV-1 vaccines: challenges and new perspectives.

Authors:  Jean-Louis Excler; Merlin L Robb; Jerome H Kim
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 5.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

Review 6.  Evolution of B cell analysis and Env trimer redesign.

Authors:  Gunilla B Karlsson Hedestam; Javier Guenaga; Martin Corcoran; Richard T Wyatt
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 7.  Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Authors:  Jean-Louis Excler; Julie Ake; Merlin L Robb; Jerome H Kim; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

8.  Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.

Authors:  Ganesh E Phad; Néstor Vázquez Bernat; Yu Feng; Jidnyasa Ingale; Paola Andrea Martinez Murillo; Sijy O'Dell; Yuxing Li; John R Mascola; Christopher Sundling; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Immunol       Date:  2015-05-11       Impact factor: 5.422

9.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

10.  Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.

Authors:  Bimal K Chakrabarti; Yu Feng; Shailendra Kumar Sharma; Krisha McKee; Gunilla B Karlsson Hedestam; Celia C Labranche; David C Montefiori; John R Mascola; Richard T Wyatt
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.